Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of TherapyCompleted
NCT05270278N/AUpdated Feb 23, 2024
Sponsor: Value Outcomes Ltd.
Asthma; Eosinophilic · Asthma Chronic · Bronchial Asthma · Asthma, Bronchial
Czechia
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)Completed
NCT00516373Phase 1Updated Feb 22, 2024
Sponsor: AstraZeneca
Ovarian Neoplasms · BRCA1 Protein · BRCA2 Protein
Belgium, Netherlands, Poland, United Kingdom
Prevalence of PD-L1 Expression in Patients With Advanced Urothelial CarcinomaCompleted
NCT03788746N/AUpdated Feb 22, 2024
Sponsor: AstraZeneca
Urothelial Carcinoma
United States
IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation TherapyCompleted
NCT03643484N/AUpdated Feb 21, 2024
Sponsor: AstraZeneca
Carcinoma, Non-Small-Cell Lung
Japan
Real-world Treatment Patterns and Associated Outcomes in Patients With Resectable Early-stage Non-small Cell Lung CancerCompleted
NCT04808050N/AUpdated Feb 21, 2024
Sponsor: AstraZeneca
Non-small Cell Lung Cancer
Australia, Egypt, Hong Kong, India, Kuwait +2 more
Type 2 Diabetes Exemplar: A Remote Care Service for North West LondonCompleted
NCT04731142NAUpdated Feb 20, 2024
Sponsor: Imperial College London
Type 2 Diabetes Mellitus
United Kingdom
Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in BrazilCompleted
NCT03836469N/AUpdated Feb 20, 2024
Sponsor: Latin American Cooperative Oncology Group
Lung Cancer, Non-small Cell
Brazil
Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic LeukemiaCompleted
NCT04964908N/AUpdated Feb 20, 2024
Sponsor: AstraZeneca
Chronic Lymphocytic Leukemia
Argentina, Brazil, Chile, Colombia, Costa Rica +12 more
A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving DurvalumabCompleted
NCT04884269N/AUpdated Feb 15, 2024
Sponsor: AstraZeneca
Carcinoma, Non-Small-Cell Lung
Japan
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib TreatmentActive Not Recruiting
NCT04169841Phase 2Updated Feb 13, 2024
Sponsor: Centre Georges Francois Leclerc
Immunotherapy
France
Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell LymphomaActive Not Recruiting
NCT05214183Phase 2Updated Feb 12, 2024
Sponsor: Nordic Lymphoma Group
MCL · Mantle Cell Lymphoma
Denmark, Finland, Norway, South Korea, Sweden
A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.Terminated
NCT05644600Phase 1Updated Feb 8, 2024
Sponsor: AstraZeneca
Healthy Subjects
United Kingdom
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxinUnknown
NCT03449251Phase 2Updated Feb 7, 2024
Sponsor: Cambridge University Hospitals NHS Foundation Trust
Cardiovascular Diseases · Type 2 Diabetes Mellitus
United Kingdom
Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube CancerCompleted
NCT04991051N/AUpdated Feb 6, 2024
Sponsor: AstraZeneca
Fallopian Tube Cancer
Kuwait, Oman, Qatar, Russia, Saudi Arabia +1 more
A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.Completed
NCT03907969Phase 1, Phase 2Updated Feb 6, 2024
Sponsor: AstraZeneca
Advanced Malignancies
United States, United Kingdom
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung CancerCompleted
NCT02789345Phase 1Updated Feb 5, 2024
Sponsor: Eli Lilly and Company
Non-small Cell Lung Cancer
United States, France, South Korea, Spain, Taiwan
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in AdultsCompleted
NCT04516746Phase 3Updated Feb 5, 2024
Sponsor: AstraZeneca
COVID-19 · SARS-CoV-2
United States, Chile, Peru
IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the USWithdrawn
NCT05970263Phase 4Updated Feb 1, 2024
Sponsor: AstraZeneca
COPD
Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe AsthmaCompleted
NCT04570657Phase 2Updated Jan 30, 2024
Sponsor: AstraZeneca
Asthma
United States, Argentina, Germany, Hungary, Poland +2 more
EGFR_IUO 3.20 Clinical Study ProtocolWithdrawn
NCT05959473NAUpdated Jan 26, 2024
Sponsor: Biocartis NV
NSCLC
PRagmatic Trial Of Messaging to Providers About Treatment of Heart Failure in the Inpatient SettingCompleted
NCT04686604NAUpdated Jan 26, 2024
Sponsor: Yale University
Heart Failure
United States
A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid TumoursCompleted
NCT04958226Phase 1Updated Jan 25, 2024
Sponsor: AstraZeneca
Solid Tumour
United States
The Drug Rediscovery Protocol (DRUP Trial)Recruiting
NCT02925234Phase 2Updated Jan 24, 2024
Sponsor: The Netherlands Cancer Institute
Cancer · Tumors · Neoplasm · Neoplasia
Netherlands
A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C MutationsWithdrawn
NCT05848843Phase 1Updated Jan 23, 2024
Sponsor: M.D. Anderson Cancer Center
Lung Cancer · Gastro-intestinal Cancer
United States
Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian CancerCompleted
NCT03117933Phase 2Updated Jan 23, 2024
Sponsor: University of Oxford
Ovarian Cancer
United Kingdom

Previous page Next page